Generic HIV combination medications, such as tenofovir/lamivudine/dolutegravir (TDF/3TC/DTG), could be produced for as little as $59 per person per year. Achieving the 95-95-95 targets based on this cost could result each year in $26 billion being saved, 630,000 fewer new HIV infections and 240,000 fewer deaths, according to a recent study by Dr Katherine Heath and colleagues published ahead of print in AIDS.
The updated UNAIDS targets for 2025 aim for 95% of those living with HIV to know their status, 95% of those who know their status to be on treatment and 95% of those on treatment to be virally suppressed. While the previous 90-90-90 targets for 2020 were met by some countries, they were not met globally. The goals of fewer than 500,000 annual new infections and 500,000 AIDS-related deaths was also not in sight in 2019, with an estimated 1.7 million new infections and 600,000 AIDS-related deaths.
Read the full story at Aidsmap.
Source : Aidsmap
Related HIV and Co-Infections News
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.